↓ Skip to main content

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

policy
1 policy source
patent
23 patents
guideline
2 clinical guideline sources

Readers on

mendeley
55 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes
Published in
Diabetes Care, July 2001
DOI 10.2337/diacare.24.7.1226
Pubmed ID
Authors
Abstract

To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy. After 8 weeks of insulin standardization and placebo (PBO) run-in, 319 type 2 diabetic patients with mean baseline HbA(1c) > or = 7.5% (8.9 +/- 1.1 to 9.1 +/- 1.3) on twice-daily insulin therapy (total daily dose > or = 30 U) were randomized to 26 weeks of additional treatment with RSG (4 or 8 mg daily) or PBO. Insulin dose could be down- titrated only for safety reasons. The primary end point was reduction of HbA(1c) from baseline. RSG 4 and 8 mg daily significantly improved glycemic control, which was unchanged on PBO. By intent-to-treat analysis, treatment with RSG 8 mg plus insulin resulted in a mean reduction from baseline in HbA(1c) of 1.2% (P < 0.0001), despite a 12% mean reduction of insulin dosage. Over 50% of subjects treated daily with RSG 8 mg plus insulin had a reduction of HbA(1c) > or = 1.0%. Neither total:HDL cholesterol nor LDL:HDL cholesterol ratios significantly changed with RSG treatment. Serious adverse events did not differ among groups. The addition of RSG to insulin treatment results in significant improvement in glycemic control and is generally well tolerated.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United States 1 2%
Italy 1 2%
United Kingdom 1 2%
Spain 1 2%
Unknown 51 93%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 12 22%
Other 6 11%
Student > Bachelor 6 11%
Student > Master 6 11%
Professor 3 5%
Other 6 11%
Unknown 16 29%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 23 42%
Agricultural and Biological Sciences 7 13%
Biochemistry, Genetics and Molecular Biology 3 5%
Nursing and Health Professions 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 2 4%
Unknown 16 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2022.
All research outputs
#3,791,064
of 34,457,357 outputs
Outputs from Diabetes Care
#4,915
of 13,230 outputs
Outputs of similar age
#4,998
of 60,149 outputs
Outputs of similar age from Diabetes Care
#25
of 73 outputs
Altmetric has tracked 34,457,357 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,230 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 29.1. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 60,149 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.